

## Completion of Cancellation of Unvested Loan Shares

**Sydney, 14 December 2017: Actinogen Medical, (Actinogen) (ASX: ACW)** advises that it has today completed the cancellation of 5,000,000 unvested loan shares.

The cancellation of the unvested loan shares was approved at the Annual General and Special General Meetings of shareholders held on 29 November 2017.

A copy of the ASIC Form 484 notifying the cancellation of the 5,000,000 unvested loan shares is attached.

Following this cancellation, the total number of shares on issue is 706,693,558.

**ENDS**

### **Actinogen Medical**

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

### **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

### **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**

## Change to company details

### Company details

Company name

**ACTINOGEN MEDICAL LIMITED**

Australian Company Number (ACN)

**086 778 476**

### Lodgement details

Who should ASIC contact if there is a query about this form?

Name

**WEBSE,PETER**

ASIC registered agent number (if applicable)

**26761**

### Signature

This form must be signed by a current officeholder of the company.

I certify that the information in this form is true and complete

Name

**PETER GORDON WEBSE**

Capacity

**Secretary**

Signature



Date signed

**14-12-2017**

## C1 Cancellation of shares

### Reason for cancellation

### Shares cancellation details

Reason for cancellation

**S.256A-S.256E Capital reduction - multiple shareholder company. A form 2560 must be lodged before capital reduction takes place**

The cancelled shares are listed below:

Share class code	Number of shares cancelled	Amount paid (cash or otherwise)	
ORD	5000000	100000.00	

Earliest Date of cancellation

**14-12-2017**

## C3 Change to share structure

The updated details for this changed share class are shown in the table below.

Share class code	Full title if not standard	Total number of shares	Total amount paid on these shares	Total amount unpaid on these shares
ORD	ORDINARY	706693558	31758828.36	0.00

Earliest date of change

**14-12-2017**